What Is LCAT and Its Function in the Body?

LCAT, short for lecithin:cholesterol acyltransferase, is an enzyme produced by the liver that circulates in your blood and performs one critical job: it converts free cholesterol on the surface of lipoproteins into cholesteryl esters, a packaged form that can be tucked into the core of HDL particles. This reaction is a key step in how your body moves excess cholesterol out of tissues and back to the liver for disposal. Without functional LCAT, HDL particles remain small and immature, cholesterol accumulates in tissues where it doesn’t belong, and the consequences range from cloudy corneas to kidney failure.

Where LCAT Comes From

Your liver is the primary factory for LCAT. Hepatocytes, the main liver cells, synthesize the enzyme and continuously secrete it into the bloodstream, where it latches onto lipoprotein particles and does its work.¹ The rate of secretion is steady over a 24-hour cycle, so under normal conditions you maintain a fairly constant supply of the enzyme in your plasma. LCAT is a glycoprotein, meaning it carries sugar chains attached to specific sites on its surface. Those sugar chains aren’t just decoration. Experiments removing them one at a time showed that glycosylation at certain positions is critical for the enzyme to fold properly, get secreted, and stay active, while glycosylation at one particular site actually restrains activity.²

The Reaction LCAT Performs

LCAT’s job, boiled down, is to grab a fatty acid from a phospholipid molecule called lecithin (phosphatidylcholine) and transfer it onto a molecule of free cholesterol. The product is a cholesteryl ester, which is far more hydrophobic than free cholesterol. That hydrophobicity matters because cholesteryl esters naturally migrate away from the surface of a lipoprotein particle and burrow into its oily core. The result is that a flat, disc-shaped HDL particle gradually inflates into a round, mature sphere as more and more cholesteryl esters pack inside it.³

LCAT doesn’t work alone. It needs a partner protein called apolipoprotein A-I (apoA-I), the main structural protein of HDL, to switch on its activity. Recent structural studies have shown that LCAT binds to a specific site formed by two adjacent apoA-I molecules wrapped around the HDL particle. The binding site spans portions of helices 4 through 7 across both apoA-I chains, creating a kind of composite landing pad.⁴ Researchers have described this as a “thumbwheel” mechanism, where apoA-I molecules rotate or shift relative to each other on the HDL surface, presenting fresh cholesterol to the enzyme for processing. Point mutations in the critical apoA-I residues can kill LCAT’s activity even though the enzyme still binds to the particle just fine, confirming that proper positioning is essential.⁵

At the atomic level, LCAT’s structure resembles a family of enzymes called alpha/beta hydrolases. Its crystal structure, solved at high resolution, reveals a core catalytic domain flanked by two extra subdomains. One subdomain contains the region that allows LCAT to nestle against lipid surfaces (a property called interfacial activation), while the other contains a “lid” that shapes the pocket where the fatty acid and cholesterol substrates fit.⁶ The overall architecture is strikingly similar to another enzyme called lysosomal phospholipase A2 (LPLA2), which helped researchers build early models of LCAT before higher-resolution structures became available.⁷

How LCAT Drives Reverse Cholesterol Transport

The most important thing LCAT does for your health is keep reverse cholesterol transport moving. Reverse cholesterol transport is the process by which cholesterol is pulled out of peripheral tissues, loaded onto HDL particles, and ferried back to the liver. When newly formed, lipid-poor HDL particles (called pre-beta HDL) pick up free cholesterol from cell membranes, LCAT goes to work converting that cholesterol into cholesteryl esters. This conversion has a dual effect: it clears free cholesterol from the particle surface, which creates room for more cholesterol to climb aboard, and it physically reshapes the particle from a small disc into a large sphere loaded with ester in the core.⁸

Those mature, spherical HDL particles then have two main fates. They can deliver cholesteryl esters directly to the liver through a receptor called SR-BI, or another protein called CETP (cholesteryl ester transfer protein) can shuttle esters from HDL to other lipoproteins for eventual clearance. The larger HDL2b particles tend to direct the cholesteryl esters LCAT produces toward the liver’s clearance machinery rather than back into potentially harmful VLDL and LDL particles.³ Without LCAT to drive this maturation, HDL stays in its immature form, the gradient that pulls cholesterol out of tissues weakens, and cholesterol begins accumulating where it shouldn’t.

What Happens When LCAT Is Missing

Mutations in the LCAT gene cause two recognized genetic conditions, both rare and inherited in an autosomal recessive pattern. The more severe form, called familial LCAT deficiency (FLD), involves a near-complete loss of enzyme activity. The milder form, called fish-eye disease (FED), involves a partial loss that primarily affects LCAT’s ability to act on HDL while sparing some of its activity on other lipoproteins.⁹

Both conditions share one hallmark symptom: progressive corneal opacification. Free cholesterol and phospholipid deposits build up in the cornea over time, giving the eyes a cloudy, grayish appearance. In fish-eye disease, the corneal cloudiness is often the most prominent clinical feature, which is how the condition got its name. The underlying mechanism in one well-characterized FED family showed that the mutant enzyme retained less than about 7% of its normal activity against HDL-type substrates.¹⁰

In full FLD, the consequences go well beyond the eyes. Patients develop normochromic anemia (a type of anemia where red blood cells are normal in color but reduced in number) and, most seriously, progressive kidney disease from lipid deposits in the glomeruli. A follow-up study of Italian FLD patients found that kidney failure occurs at a median age of 46, with high plasma levels of unesterified cholesterol serving as a predictor of how quickly kidney function declines.¹¹ Renal disease is the leading cause of illness and death in FLD, and once a patient receives a kidney transplant, the disease can recur in the donor organ because the underlying enzyme deficit persists in the bloodstream.

Acquired LCAT Deficiency

You don’t need a genetic mutation to end up short on LCAT. Certain diseases can cause an acquired deficiency. The best-studied example is nephrotic syndrome, a kidney condition characterized by heavy protein loss in the urine. Because LCAT is a relatively small plasma protein, it can leak through damaged kidney filters along with albumin and other proteins. In animal models of nephrotic syndrome, the liver continues producing LCAT mRNA at normal rates, but heavy urinary losses drag down the circulating enzyme concentration.¹² The result mirrors some features of genetic LCAT deficiency: impaired cholesterol esterification, abnormal HDL profiles, and the dyslipidemia characteristic of kidney disease. Liver disease, which impairs LCAT production at the source, is another recognized cause of acquired deficiency.

LCAT, HDL, and Heart Disease

Given that LCAT raises HDL cholesterol and promotes reverse cholesterol transport, you might expect that more LCAT would straightforwardly protect against heart disease. The reality is more complicated, and this is one area where the science genuinely surprised researchers.

A large prospective study nested within the EPIC-Norfolk population measured LCAT levels in about 2,800 apparently healthy men and women and followed them for six years. LCAT levels did not differ between people who later developed coronary artery disease and those who stayed healthy. When the data were split by sex, higher LCAT levels were actually associated with increased heart disease risk in women. LCAT correlated positively with LDL cholesterol and triglycerides but, unexpectedly, showed no association with HDL cholesterol in this general-population sample.¹³ A separate study reinforced this picture, finding that higher LCAT activity was associated with a roughly 60% increased hazard of cardiovascular events compared to lower activity, and that high LCAT activity appeared to blunt the protective benefit normally associated with high HDL cholesterol.¹⁴

How do you reconcile this with the fact that people who completely lack LCAT have abnormally low HDL? The answer likely comes down to context. In genetic LCAT deficiency, the entire HDL maturation pathway is broken, producing a constellation of lipid abnormalities. But in the general population, where everyone has functional LCAT, having somewhat more versus somewhat less enzyme activity is tangled up with overall metabolic health, triglyceride levels, and the composition of lipoproteins in ways that don’t simplify into “more is better.” LCAT sits at a crossroads of lipid metabolism, and boosting it doesn’t automatically mean better outcomes if the downstream pathways are already saturated or if the extra cholesteryl esters end up being transferred into atherogenic particles instead of cleared by the liver.¹⁵

Efforts to Use LCAT as a Treatment

Despite the complexity around cardiovascular risk, the idea of giving people extra LCAT as medicine has attracted serious investment, particularly for patients with genetic LCAT deficiency and potentially for those recovering from a heart attack. The most advanced approach is a recombinant human LCAT protein called MEDI6012, developed for intravenous infusion. In phase 2a trials, MEDI6012 raised HDL cholesterol in a dose-dependent manner. The highest dose tested increased HDL cholesterol by about 144% compared to placebo, while also boosting markers of functional reverse cholesterol transport and reducing the number of atherogenic LDL particles.¹⁶ The drug was well tolerated across multiple ascending doses.¹⁷

Beyond injectable protein, researchers are hunting for small-molecule pills that could activate the LCAT already in a patient’s bloodstream. One compound called DS-8190a doubled LCAT activity in monkeys after a week of oral dosing, raising HDL cholesterol without dramatically changing non-HDL cholesterol. In mice engineered to develop atherosclerosis, DS-8190a reduced plaque area by about 48% at the higher dose.¹⁸ Structural studies have helped explain how these activators work: they bind to LCAT’s membrane-binding domain, apparently stabilizing the enzyme’s active conformation. This is encouraging for patients with certain FLD mutations, because some of those mutant enzymes retain partial function that a small molecule could potentially amplify.¹⁹

All of this remains early-stage. No LCAT-based therapy has yet reached the market, and the cardiovascular data discussed above serve as a reminder that raising HDL cholesterol is not automatically the same as reducing heart attacks. The hope is that restoring proper reverse cholesterol transport function, rather than simply lifting a number on a lab panel, is the meaningful therapeutic target.

Can Diet or Exercise Change Your LCAT Levels?

Exercise has long been associated with higher HDL cholesterol, so it’s natural to wonder whether it works partly through LCAT. The evidence is mixed and somewhat species-dependent. In mice, voluntary exercise raised LCAT activity across groups eating different levels of dietary protein.²⁰ In humans, though, a study of exercise training found no significant change in LCAT protein levels, and individual changes within the exercise group were unrelated to distance run or weight lost.²¹ Whatever mechanism links exercise to HDL improvements in people, it doesn’t appear to run primarily through more LCAT protein in the blood.

Dietary fat composition is a different story. In isolated rat liver cells, certain 18-carbon fatty acids (including oleic, stearic, and linoleic acids) boosted LCAT secretion by 50 to 100%, while shorter-chain fats like butyric and lauric acid had no effect.²² In a human feeding study, moderate intake of alpha-linolenic acid (from rapeseed oil) and myristic acid (from dairy fat) together boosted LCAT activity by about 152% compared to a control diet, along with an improvement in the total-to-HDL cholesterol ratio.²³ These are intriguing findings, though they don’t yet translate into specific dietary prescriptions for managing LCAT activity. What they do suggest is that the type of fat you eat influences how actively your body processes cholesterol on lipoproteins, in ways that go beyond simple “good fat, bad fat” labels.

LCAT’s Involvement Beyond HDL

Although LCAT is best known for its work on HDL, it also esterifies cholesterol on LDL and other lipoproteins. Mouse studies have shown that knocking out LCAT significantly lowers the cholesteryl ester content of LDL particles, confirming that LCAT contributes meaningfully to the cholesteryl ester pool in LDL, not just HDL.²⁴ A different intracellular enzyme called ACAT2 handles most of the cholesteryl ester packaging that goes into newly assembled VLDL particles in the liver, so the two enzymes divide the labor: ACAT2 works inside cells during lipoprotein assembly, while LCAT works outside cells in the bloodstream after lipoproteins are already circulating.

LCAT also has connections to oxidative stress. In mice completely lacking LCAT, transferring a functional LCAT gene transiently lowered markers of oxidative damage, suggesting the enzyme’s cholesterol-packaging activity may have secondary antioxidant effects.²⁵ Whether this matters clinically in humans with normal LCAT function is unclear, but it adds another layer to the enzyme’s biological significance beyond straightforward cholesterol shuttling.

When researchers gave recombinant LCAT to human subjects and tracked what happened to the various lipoprotein classes in detail, they found that the metabolism of apoB100-containing lipoproteins (the family that includes LDL and VLDL) was not significantly altered.²⁶ In other words, adding extra LCAT changed the HDL side of the equation without reshuffling the atherogenic lipoprotein pool in humans. That finding matters because it suggests that any therapeutic benefit from LCAT supplementation would come specifically from improving HDL function rather than from changing LDL metabolism.

Sugar Chains and Enzyme Fine-Tuning

LCAT carries four sites where sugar chains can be attached. Each site plays a distinct role. In one set of experiments, removing the sugar chain at position 84 slashed enzyme activity to about a quarter of normal and reduced the amount of enzyme that made it out of cells. Removing the chain at position 272 was even more severe: no functional enzyme was secreted at all, indicating that this particular sugar is essential for the protein to fold or travel through the cell’s secretion machinery.²⁷ Removing the chain at position 384, by contrast, actually improved the enzyme’s affinity for its substrates without hurting secretion. And stripping all four sugar chains at once produced an enzyme that was barely secreted and almost nonfunctional, with activity dropping to about 5% of the wild-type level.²

These findings have practical relevance for anyone trying to manufacture recombinant LCAT as a drug. The cell system used to produce the protein must be capable of attaching the right sugars at the right positions, or the resulting enzyme will not work properly in the bloodstream. This is one of the reasons why producing effective LCAT therapeutics has been technically challenging and why cryo-electron microscopy and other structural tools continue to refine our understanding of how the enzyme is assembled and activated at the molecular level.²⁸